2020CSCO丨郭军教授:中国黑色素瘤科研初具蓝图,将来需多中心协同推进
盘点2020|斯璐:黑色素瘤治疗发展盘点
解码黑色素瘤青年探索者斯璐:她亦曾想过放弃
积石成山丨中国黑色素瘤表率性论著周期总结
历史回顾丨中国临床肿瘤学年度科研发展2015-2021黑色素瘤部分要紧发展+值得关注的发展回顾
● 中国原创黑色素瘤 ●
●●●Original melanoma of China●●●
J Clin Oncol(3篇),Ann Oncol(2篇),Clin Cancer Res(3篇),J Immunother Cancer(2篇),Eur J Cancer(4篇)
中国原创黑色素瘤
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfxclrg9CxGJxDy0sJibI8m1tFEfv5WNRnaqp2puX1E3GvRuenpg0PuAXQ/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
Chin J Cancer Res
Chin J Cancer ResA phase II study of fotemustine plus dacarbazine with dendritic cell vaccines as first-line therapy for Chinese patients with advanced acral lentiginous melanoma(2009)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfxVbegqMmatjFcicLjBtXLqn4rlofFdHVZMo5ZB8wnKZJ1ZEibCiaIOEQkQ/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
Eur J Cancer
Eur J Cancer A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients(2011)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfxLDibuEIIfYrBX5KGMrliaRK5BYGJOffMPiaySXxSPxbJRYSQkY8YHNAww/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
J Clin Oncol
J Clin Oncol Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification(2011)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfxAEvfMrBIALT09CuhPYVocKgyXkBGjcyCQOETaOTm6TwB3dCz7l7l3w/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
Mol Ther
Mol TherA phase II, randomized, double-blind, placebo-controlled multicenter trial of endostar in patients with metastatic melanoma(2012)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfxYNsBU67s9LuYzUUvQ1qLF7e75eQ4jYZJrNXZSwQo0NPY2JvvZnDfqQ/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
Clin Cancer Res(ChiCTR-TRC-11001798)
Clin Cancer Res Phase II randomized trial comparing high-dose IFN-α2b with Temozolomide plus Cisplatin as systemic adjuvant therapy for resected mucosal melanoma(2013)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfx2S8iarGFn0xo4AYib0PeS5uZYumopsIZ14v4xNmWZrnRHtRzCbxERrUA/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
Ann Oncol(NCT01028222)
Ann Oncol Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial(2017)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfxYGvEz81jxwicyk2zEQ84iaLL4NelRNibGv8h5a8DfK8kNdvHuQ18QNb9A/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
BMC Cancer(NCT01910181)
BMC CancerVemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study(2018)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfxaZ58R1ic8c2yib4xsEX2pIoxGyakfJmVFUGOrv6sXXj2ewtvJ70quLnA/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
Transl Oncol(KEYNOTE 151)
Transl Oncol A phase Ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma(KEYNOTE-151)(2019)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfx0Kzsofn8OSzhNtynchVZ3Hhaok1NvBJ5K6ccBfn53DJOJVLjVb6Z9Q/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
J Clin Oncol(NCT03086174)
J Clin Oncol Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial(2019)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfxcVAGx9HNyKSv56IichXLfSjZdBiagLmhNtva4VIJK9icD0qtpaauV5NbQ/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
Eur J Cancer(NCT02083354)
Eur J CancerOpen-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma(2020)
![](https://mmbiz.qpic.cn/mmbiz_png/ibGx5uB9xrIsxrzdhBGvicxfIKAh09Vhic109r5zIK2JcxDenic3re0wiceYsQEE6VfKibNFzAc4kjTOvkAPiciaV0wW2g/640?wx_fmt=png&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
Clin Cancer Res(NCT03013101)
Clin Cancer ResSafety, efficacy and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial(2020)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfxQWZcLic5YA6MgDBrD8cbkLG8pdc4ZicwrPqqZZBkS09UwlaQKrsSMwCg/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
J Immunother Cancer(CTR20160872)
J Immunother Cancer Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study(2020)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfxYRJfpufzAkYDd0TQZdxtwMtMjLuEdb2ctglXiaVxW7wEACaJafzJICA/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
J Clin Oncol(NCT02023710)
J Clin Oncol Randomized phase II study of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma(2021)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrItG4d0cLeaXWUicCGlRWf1eSkM6sNdNicDkOL434zmuuDbTJpmbl3DiaTAiaxC2ITMhhJanUnm2YibHaZw/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
J Immunother Cancer(NCT03086174)
J Immunother Cancer Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis(2021)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsVE2rWoI1ew0Bnq1jXryOHKs0t9AuxYhRwCsQPhT7ASicC6YWHkM9B9BQAgfMBkrtvFz2sJSUBLOw/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
Front Oncol(NCT02083354)
Front Oncol Overall survival of patients with unresectable or metastatic BRAF V600-mutant acral/cutaneousmelanoma administered dabrafenib plus trametinib: long-term follow-up of a multicenter, single-arm phase IIa trial(2021)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrItG4d0cLeaXWUicCGlRWf1eShialJLQ0FjOwaiaZUia8Uqjzy1aSRXibibpKKzVQ0cKTPRf4vyBZjZpFwQw/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
Eur J Cancer(NCT03454919)
Eur J Cancer Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway(2021)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsPZlOS2jNBhhNVxZUgLD3uWq6ic1kwJnLMj8fPrVLkAY0iamLRAHD7oVicpnQeaon2mndibXib2wEMGzQ/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
Melanoma Res(NCT03422445)
Melanoma Res Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy(2022)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIv8vMsZIH3qHVhMHkyX9oOianDOghEpNGx7JxEnLrkJFxKEGgZm3DLibMnjKDddt8QusPzIp1cLZDbg/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
J Immunother Cancer(CTR20140631 and CTR20150881)
J Immunother Cancer OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase Ib study(2022)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsicRtcTjOqmlJouic8VY1dla7OjJFPyv7LyXpzHJhVRibDuqFJ1KTZDxlx8AygPzlNLcqAJQRNtvqTg/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
Ann Oncol(NCT03178123)
Ann Oncol Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial(2022)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsnxrMjuV3QKVaVRFickKiaCkyviaJLicuHMPBNOfakEAPNPscSVZJaIqH2fRLkL8591tD85MAhaN2MgA/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
BMC Cancer(NCT02738489)
BMC Cancer Safety, activity and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study(2022)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrItPRZEObicSWsf7iaEb9jaI0nibMZzqColJKCbQmibqQnZaEctsyvax0ZkbgOOVeIRNN5AvR23o6LkLrg/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
Clin Cancer Res(NCT04091217)
Clin Cancer ResAtezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: a multicenter, open-label, single-arm phase II study(2022)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrItE7N12nehNRBTAMkyvibH67jnPkuncnBaT235HQg07xzzCRJJvQALgwiaaRv504K6FA4MTzwKj2zgQ/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
Eur J Cancer(NCT03932253)
Eur J Cancer A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma(2022)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsicRtcTjOqmlJouic8VY1dlaGNEeKAbajVj0ZRbWuawf4lSoQ1Q0BvpB2AqCoRic6tpFf4BBicVnBZKQ/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
Front Oncol(KEYNOTE 151)
Front Oncol Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study(2022)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIvaNRByuviclDWNYg9jrb6mcg7OxrfcqFa9kicypbib9EcF2icSls8QpNxfjdftgFga4K2bVubR6AMYog/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp) 整理者
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsPZlOS2jNBhhNVxZUgLD3uKxiaT3TeLfPHDsI6X6Scl70VDWYb4hBdIsbibrMgRKJqowBvxcibUzSGw/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIu8WZUU26yZ4dmuHSFDelIWB3LdaHGlTQuCT03CyalqYQQRpQMiagSzPjc1U6oiaLzBiaweNcDuOVOQQ/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIuQsibmgbgU2qOpBTyfPiapDjBtMCnBnGwJlnkkQ1Dr5zuF2qnJibW0V8GZFibfPiaDzmghCgss4c1JqcA/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
![](https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsoKv9F16WwwkDU6GEMR5eqh3YwAjvic7aa6UDKxBALrKjzKpt22eJJl89liaMYxLRQFHGpz3Z83t4Q/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp)
|